Pomerantz Law Firm Files Class Action Against Inovio Pharmaceuticals for Securities Violations

Pomerantz Law Firm's Class Action Against Inovio Pharmaceuticals

Pomerantz LLP has made headlines by filing a class action lawsuit against Inovio Pharmaceuticals, Inc., along with certain key officials from the company. This legal action was launched in the United States District Court for the Eastern District of Pennsylvania and is significant for those who acquired Inovio securities within the defined class period, from October 10, 2023, to December 26, 2025.

The lawsuit, which has been documented under docket number 26-cv-00803, aims to seek restitution for investors who may have suffered financial losses due to the alleged violations of federal securities laws by Inovio and its executives. The class action is particularly targeted at anyone outside the defendants who purchased Inovio securities during this timeline, with plaintiffs urged to act quickly. Investors have until April 7, 2026, to formally request appointment as lead plaintiff in this case.

Inovio Pharmaceuticals is known for its focus on pioneering DNA medicines aimed at combating diseases, notably those associated with human papillomavirus (HPV). Its innovative product candidates include INO-3107, which targets the treatment of recurrent respiratory papillomatosis (RRP). The company has often touted expectations of FDA approval on an accelerated basis for INO-3107, projecting that it would secure a biologics license application (BLA) by mid-2024.

However, around the same time it was making optimistic claims to investors about rapid advancements, Inovio was also conducting multiple private securities offerings, netting millions in profits with each offering. Despite the favorable statements made about the company’s prospects, the lawsuit alleges that these communications were misleading. Specifically, it points out that the defendants knew there were significant deficiencies in the manufacturing of Inovio's proprietary CELLECTRA device, which would hinder the timely submission of the INO-3107 BLA to the FDA.

Furthermore, the legal complaint suggests that Inovio lacked sufficient data to support the eligibility of INO-3107 for expedited approval, thereby overstating its potential regulatory and commercial outcomes. The misleading nature of the representations made is a central tenet of the class action claim.

Awareness around these allegations increased significantly following a press release from Inovio on August 8, 2024, during which the company disclosed a delay in the expected FDA submission for the INO-3107 BLA, now projected for mid-2025 due to manufacturing issues with the CELLECTRA device. Following this announcement, Inovio's stock price took a notable dip of 3.1%, dropping to $8.44 per share.

The situation worsened further on December 29, 2025, when it was revealed that the FDA accepted the INO-3107 BLA for review on a standard timeline instead of the desired accelerated mode. This news sent shockwaves through the market, resulting in a dramatic 24.45% drop in stock price to close at $1.73 per share.

The Pomerantz Law Firm, renowned for its expertise in corporate, securities, and antitrust class litigations, underscores its commitment to fighting for the rights of investors affected by potential securities fraud. Founded over 85 years ago, the firm continues its legacy of holding companies accountable for their actions.

For those interested in pursuing this legal avenue, further information is available through the Pomerantz website at www.pomerantzlaw.com. Interested parties are encouraged to reach out to Danielle Peyton at the provided contact information to discuss the implications of the lawsuit and potential involvement in this significant case.

This unfolding situation serves as a crucial reminder of the volatility in pharmaceutical stocks and the importance of transparency in communications from public companies to their investors.